Dr. Agrawal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5841 S Maryland Ave
Chicago, IL 60637Phone+1 888-824-0200Fax+1 773-702-6809
Summary
- Dr. Nishant Agrawal is a head and neck surgical oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 16 years. He specializes in head & neck oncologic surgery and is experienced in squamous cell carcinoma, thyroid cancer, head and neck oncology, and oral and oropharyngeal neoplasms. He recently co-edited a textbook titled Difficult Decisions in Head and Neck Oncologic Surgery (https://link.springer.com/book/10.1007%2F978-3-030-15123-2).
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Head & Neck Surgical Oncology/Microvascular Reconstruction, 2008 - 2008
- Johns Hopkins UniversityResidency, Otolaryngology - Head and Neck Surgery, 2002 - 2008
- Johns Hopkins University School of MedicineInternship, Transitional Year, 2001 - 2002
- Johns Hopkins University School of MedicineClass of 2001
Certifications & Licensure
- IL State Medical License 2015 - 2026
- MD State Medical License 2008 - 2026
- IN State Medical License 2020 - 2025
- NY State Medical License 2007 - 2009
- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
- Member American Head and Neck Society
- Most Compassionate Doctor American Registry
- Join now to see all
Clinical Trials
- Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx Start of enrollment: 2010 Mar 01
Publications & Presentations
PubMed
- A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors.Brian Golbourn, Ben Ho, Andrew Bondoc, Amanda Luck, Xiaolian Fan
Neuro-Oncology. 2024-10-03 - 2 citationsOutcomes of Impella 5.0 and 5.5 for cardiogenic shock: A single-center 137 patient experience.Yeahwa Hong, Nishant Agrawal, Nicholas R Hess, Luke A Ziegler, McKenzie M Sicke
Artificial Organs. 2024-07-01 - 1 citationsNeoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.Ari J Rosenberg, Nishant Agrawal, Aditya Juloori, John Cursio, Zhen Gooi
JAMA Oncology. 2024-07-01
Journal Articles
- OPTIMA: A Phase II Dose and Volume De-Escalation Trial for Human Papillomavirus-Positive Oropharyngeal CancerL Portugal, E A Blair, J M Melotek, M W Lingen, N Agrawal, A Dekker, Z Gooi, D T Ginat, C C Foster, E E Vokes, D J Haraf, Annals of Oncology
- Head and Neck MassesNishant Agrawal, Zhen Gooi, ScienceDirect
Books/Book Chapters
Press Mentions
- Privo Technologies, Inc. Announces Publication in Nature CommunicationsAugust 24th, 2022
- COVID-19 Saliva Test as Accurate as Swabs, UChicago Research FindsJune 18th, 2020
- Saliva Tests for COVID-19 Could Replace Painful Nasal Swabs, U. Of C. Researchers SayJune 16th, 2020
- Join now to see all
Professional Memberships
- Fellow
- Member
- Member
Other Languages
- Hindi, Urdu
External Links
- UChicago Medicinehttp://uchicagomedicine.org
- Bio Pagehttps://www.uchicagomedicine.org/find-a-physician/physician/nishant-agrawal
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: